Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 33 for “"Meningioma"”.
-
Intensity modulated radiotherapy for skull base meningioma
Meningioma is a primary central nervous tumour (CNS) affecting mostly adults. Skull base meningiomas cause morbidity (and occasionally mortality) by compressing adjacent critical organs, and the aim of treatment is to optimise and preserve CNS function. Radiotherapy is an effective treatment for …
-
Proteomic analysis of genetically stratified grade-I meningioma
Introduction: Meningioma is the most common primary intracranial tumour. Although often benign in nature, at least 20% have high rates of recurrence. Surgical resection and radiotherapy are the main therapeutic approach, yet tumour location can hamper complete resection and chemotherapies are …
-
Analysis of Hippo pathway signalling in schwannoma and meningioma
… tumours of the nervous system, schwannoma and meningioma. A large group of schwannomas and meningiomas display the inactivation of the NF2 gene. The NF2 gene codes for the tumour suppressor protein Merlin and its loss is associated with a multitude of pro-tumourigenic mechanisms leading to the …
-
Targeting Aldehyde Dehydrogenases in NF2-null Meningioma and Schwannoma
Meningioma and schwannoma are tumours of the brain and nervous system that are frequently driven by loss or mutation of the gene NF2, which encodes the tumour suppressor protein Merlin. Dysregulated Hippo pathway signalling, caused by NF2 loss, drives overexpression of aldehyde dehydrogenase 1A1 …
-
Transorbital Endoscopic Surgery for Sphenoid Wing Meningioma: Long-term Outcomes & Surgical Technique
Sphenoid wing meningiomas are benign tumors that result in proptosis, visual impairment and pain. Traditional open surgical approaches are associated with significant morbidity. Transorbital endoscopic surgery has been developed as a minimally invasive approach to gain access to these tumors and …
-
Identifying the basis for anticancer synergy with PAC-1, with applications to meningioma
Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-12-01
-
Phase I Clinical Trial of Recombinant Oncolytic Newcastle Disease Virus for Intracranial Meningioma
Meningioma is one of the most commonly diagnosed intracranial tumors in dogs and humans. Treatment failures resulting in local recurrence and death remain common in tumors of high grade, prompting a need for additional therapeutic options that are both effective and affordable. Genetic modification …
-
The development and validation of a novel patient-derived 3D meningioma cell culture model
Meningiomas are the most frequent intracranial brain tumours. Current treatment options of surgery and radiotherapy are sometimes insufficient and effective systemic therapies remain unestablished. The development of accurate in vitro systems to model the complexity of meningioma pathology is …
-
Evaluation of miR-497 & miR-219 as non-invasive biomarkers for meningioma and glioma
… current WHO classification aids in predicting meningioma and glioma recurrence and prognosis. However, there is a dearth of circulating biomarkers with clinical value for meningioma diagnosis and classification. Circulating miRNAs have shown potential as cancer biomarkers in various tumours. …
-
The Role of Hippo Signalling in Merlin Null Tumours of the Nervous System
Meningiomas and schwannomas are mostly benign tumours of the nervous system that currently have no clinically approved treatments apart from surgical resection. The tumour suppressor Moesin-Ezrin-Radixin-Like Protein (Merlin) is deleted in 50-60% and 70% of meningiomas and schwannomas respectively. …
-
The relationship between docohexanoic acid (DHA) and L-serine, providing an insight into the biochemistry of meningioma
… due to their locality. Such cancer types include meningioma and glioma which are the most common brain tumours diagnosed. An initial study involving human meningioma tissue revealed unusually high levels of the phosphatidylserine enriched with docosahexaenoic acid (DHA). In this study, the …
-
Exploring the Potential use of TEAD Inhibition as Part of a Combination Therapy for NF2-Deficient Schwannoma and Meningioma.
… resulting in the development of schwannoma, meningioma and ependymoma tumours. Although surgical resection and adjuvant radiotherapy can be used, new avenues of therapeutic development are essential to target inoperable and recurrent tumours. Previous studies evaluating small molecule TEAD …
-
Exploring the immune landscape of the tumour microenvironment in meningiomas and the role of immune infiltration in meningioma models
Background: Meningiomas are the most common primary intracranial tumours, ranging from benign to highly aggressive forms. While surgery is effective for low-grade meningiomas, certain grade 1 tumours, as well as grade 2, 3, and recurrent cases are more aggressive and require new therapeutic …
-
Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours
Although schwannomas and meningiomas are generally benign and slow-growing, the mass effect of either tumour within the nervous system causes life-altering symptoms. Individuals with NF2-related schwannomatosis may develop schwannomas and meningiomas, increasing tumour burden. The primary treatment …
-
Investigating the role of TAM (TYRO3, AXL and MERTK) family receptors in merlin deficient tumours
… 2 (NF2)-related tumours including schwannomas, meningiomas and ependymomas. These tumours can also occur spontaneously in non-NF2 patients. The only available treatments for this group of tumours are surgery and radiosurgery/radiotherapy. Hence, there is an urgent need for new effective …
-
The identification of biomarker differences between grade I and II meningiomas: Fibulin-2 is a novel biomarker for differentiating grade II from grade I meningiomas
… clinical management, prognosis and follow-up of meningiomas, facilitated by recent advances in meningioma genomics. WHO grade II meningiomas remain a controversial group of CNS tumours to diagnose/treat, compared to the more prevalent and extensively researched grade I tumours. Aim: To identify …
-
The Potential of CRL4-DCAF1 and KSR1 as Therapeutic Targets in Low-grade Merlin-Deficient Tumours
… of tumour formation, including schwannoma, meningioma and ependymoma. These tumours can occur sporadically or as part of the genetic condition Neurofibromatosis type 2 (NF2) and cause significant morbidity. The current treatment options are restricted to surgery and radiotherapy, which are …
-
Unbiased global proteomic profiling of patient-derived meningiomas of all grades to identify molecular signatures of differentially expressed proteins and phosphoproteins.
Meningioma is the most frequent primary intracranial tumour. Surgical resection remains the main therapeutic option as pharmacological intervention is still hampered by the poor knowledge of the molecular signature of these tumours. In order to elucidate the proteomic profiling of meningiomas and …
-
Identifying Common Therapeutic Targets in Merlin-deficient Brain Tumours
… nervous system tumours, primarily schwannoma, meningioma and ependymoma. NF2 is characterised by loss of the tumour suppressor protein Merlin, caused by bi-allelic mutations of the encoding gene NF2 or by loss of heterozygosity. These tumours can occur either sporadically or as part of the NF2 …
-
Endogenous retroviral proteins as potential drug targets for merlin-deficient tumours
… of the nervous system such as schwannomas, meningiomas and ependymomas. Current surgical treatments and radiotherapy for this group of tumours are not fully effective and there is an urgent need for new therapeutic options. Human endogenous retroviruses (HERVs) are retroviruses that have …
Page 1 of 2